Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of OKI-179 in Advanced Solid Tumors
NCT03931681Phase 1Completed
- Sponsor
- OnKure Therapeutics
- Start
- May 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bocodepsin in solid tumor (advanced stage), sponsored by OnKure Therapeutics. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 2 years and Adverse Events at 2 years. Started May 2019; status: completed.
02
Drugs
bocodepsin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03931681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931681.